BR112013022085A2 - composição compreendendo receptor gama ativado por proliferador de peroxissoma - Google Patents

composição compreendendo receptor gama ativado por proliferador de peroxissoma

Info

Publication number
BR112013022085A2
BR112013022085A2 BR112013022085A BR112013022085A BR112013022085A2 BR 112013022085 A2 BR112013022085 A2 BR 112013022085A2 BR 112013022085 A BR112013022085 A BR 112013022085A BR 112013022085 A BR112013022085 A BR 112013022085A BR 112013022085 A2 BR112013022085 A2 BR 112013022085A2
Authority
BR
Brazil
Prior art keywords
composition
peroxisome proliferator
gamma receptor
activated gamma
proliferator activated
Prior art date
Application number
BR112013022085A
Other languages
English (en)
Inventor
Heiko Barg
Rainer Pooth
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of BR112013022085A2 publication Critical patent/BR112013022085A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

resumo patente de invenção: "composição compreendendo receptor gama ativado por proliferador de peroxissoma". a presente invenção refere-se a uma composição injetável compreendendo receptor gama ativado por proliferador de peroxissoma para administração subcutânea e um método para melhorar as imperfeições da pele, em que a composição injetável é administrada por via subcutânea na área de imperfeições da pele que compreende as etapas: a) identificar uma região de imperfeições da pele, b) administrar uma quantidade segura e cosmeticamente eficaz da composição por via subcutânea na área de imperfeições da pele.
BR112013022085A 2011-03-01 2012-02-29 composição compreendendo receptor gama ativado por proliferador de peroxissoma BR112013022085A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161447726P 2011-03-01 2011-03-01
EP11156450 2011-03-01
PCT/EP2012/053414 WO2012117013A1 (en) 2011-03-01 2012-02-29 Composition comprising peroxisome proliferator-activated receptor-gamma (ppar)

Publications (1)

Publication Number Publication Date
BR112013022085A2 true BR112013022085A2 (pt) 2016-08-09

Family

ID=44260780

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013022085A BR112013022085A2 (pt) 2011-03-01 2012-02-29 composição compreendendo receptor gama ativado por proliferador de peroxissoma

Country Status (12)

Country Link
US (1) US20130331332A1 (pt)
EP (1) EP2680809A1 (pt)
JP (1) JP2014509324A (pt)
KR (1) KR20140027943A (pt)
CN (1) CN103442676A (pt)
AU (1) AU2012222380A1 (pt)
BR (1) BR112013022085A2 (pt)
CA (1) CA2825568A1 (pt)
MX (1) MX2013009842A (pt)
RU (1) RU2013142169A (pt)
WO (1) WO2012117013A1 (pt)
ZA (1) ZA201305811B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140147950A (ko) * 2013-06-20 2014-12-31 서울대학교산학협력단 필러와 보틀리눔 독소를 포함하는 피부 주름, 노화 개선 또는 신경근육 관련 질환 치료용 조성물
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
FR3029787B1 (fr) * 2014-12-10 2019-11-29 L'oreal Composition nettoyante a base a base d'un polyethylenegycol, d'un polyether ester et d'un agent de suspension polymerique
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
CA3016464A1 (en) 2016-03-08 2017-09-14 Soo-Young Kang Long lasting cosmetic compositions
CA3074845A1 (en) 2017-09-13 2019-03-21 Living Proof, Inc. Color protectant compositions
AU2018333932B2 (en) 2017-09-13 2024-05-02 Living Proof, Inc. Long lasting cosmetic compositions
WO2019099966A1 (en) 2017-11-20 2019-05-23 Living Proof, Inc. Properties for achieving long-lasting cosmetic performance
CN112041365A (zh) 2018-04-27 2020-12-04 生活实验公司 持久性化妆品组合物
CN109568567A (zh) * 2019-01-15 2019-04-05 武汉德丽福生物科技有限公司 一种微针减肥贴片及其制备方法
CN109925501A (zh) * 2019-04-26 2019-06-25 贝亲母婴用品（上海）有限公司 一种用于改善皮肤屏障的组合物
KR20220079563A (ko) * 2019-09-16 2022-06-13 인스티튜트 오브 주올로지, 차이니즈 아카데미 오브 사이언스 조직 재생을 위한 방법 및 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436993B1 (en) * 1999-07-13 2002-08-20 The Salk Institute For Biological Studies Use of RAR antagonists as modulators of hormone mediated processes
JP2004532230A (ja) * 2001-04-30 2004-10-21 アラクノーバ・セラピューティックス・リミテッド Ｐｐａｒ−ガンマアクチベーターを使用する瘢痕化および関連状態の処置
US20040101959A1 (en) * 2002-11-21 2004-05-27 Olga Marko Treatment of tissue with undifferentiated mesenchymal cells
FR2862870A1 (fr) * 2003-12-01 2005-06-03 Galderma Res & Dev Utilisation d'activateurs de recepteurs ppar en cosmetique et dermatologie.
ZA200802546B (en) * 2005-08-29 2009-10-28 Healor Ltd Methods and compositions for prvention and treatment of diabetic and aged skin
FR2904549B1 (fr) * 2006-08-03 2012-12-14 Sederma Sa Composition comprenant de la sarsasapogenine
US20090291986A1 (en) * 2008-05-22 2009-11-26 Apostolos Pappas Composition and method of treating facial skin defect
TW201103572A (en) * 2009-05-04 2011-02-01 Neostem Inc Method and composition for restoration of age-related tissue loss in the face or selected areas of the body

Also Published As

Publication number Publication date
CA2825568A1 (en) 2012-09-07
KR20140027943A (ko) 2014-03-07
RU2013142169A (ru) 2015-04-10
EP2680809A1 (en) 2014-01-08
JP2014509324A (ja) 2014-04-17
WO2012117013A1 (en) 2012-09-07
CN103442676A (zh) 2013-12-11
US20130331332A1 (en) 2013-12-12
MX2013009842A (es) 2014-03-12
AU2012222380A1 (en) 2013-08-22
ZA201305811B (en) 2014-04-30

Similar Documents

Publication Publication Date Title
BR112013022085A2 (pt) composição compreendendo receptor gama ativado por proliferador de peroxissoma
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
MX362626B (es) Métodos para tratar pacientes pediátricos usando dexmedetomidina..
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
BR112014016085A2 (pt) composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
BR112016002171A2 (pt) método, composição estéril e injetável e método para preparar uma composição estéril e injetável
BR112015000136A2 (pt) fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento
BR112014015482A8 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
MY192033A (en) Method of dosing and use of soft anticholinergic esters
MX366076B (es) Vitamina d3 y analogos de la misma para tratar alopecia.
AR092993A1 (es) Laquinimod para reducir el daño talamico en la esclerosis multiple
BR112014009785A8 (pt) método para tratar ou reduzir efp
EP2558102A4 (en) SYNERGISTIC INTERACTION OF AT LEAST ONE COMPONENT OF VITAMIN E AND TYROSINASE INHIBITORS FOR DERMATOLOGICAL APPLICATIONS
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
MX347927B (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
BR102013003570A8 (pt) Composições de plasma rico em plaquetas
MY157513A (en) A water-in-oil type emulsion for treating a disease of the eye
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
BR112015030664A2 (pt) combinação farmacêutica de um inibidor de pi3k e um agente desestabilizador de microtúbulos
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
JP2013520447A5 (pt)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]